Measuring acceptable treatment failure rates for community-acquired pneumonia: Potential for reducing duration of treatment and antimicrobial resistance

Infection Control and Hospital Epidemiology

Volumn 29, Issue 2, 2008, Pages 137-142

  Kaye, Keith S ^a   Harris, Anthony D ^b,c   McDonald, Jay R ^c,d   Strausbaugh, Larry J ^e   Perencevich, Eli ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; MEASUREMENT; METHODOLOGY; NORTH AMERICA; OUTPATIENT; PHYSICIAN; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DATA COLLECTION; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PNEUMONIA, BACTERIAL; QUESTIONNAIRES; RESEARCH DESIGN; TREATMENT FAILURE;

EID: 39449125658     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/526436     Document Type: Article

References (30)

1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis 2007; 44: S27-S72.
3. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-760.
4. MASCOT pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360:835-841.
5. Schönwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5-g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection 1999; 27:198-202.
6. Levy SB. Confronting multidrug resistance: a role for each of us. JAMA 1993; 269:1840-1842.
7. File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39(suppl 3):S159-S164.
8. Nuermberger EL, Bishai WR. Antibiotic resistance in S. pneumoniae: what does the future hold? Clin Infect Dis 2004; 38(suppl 4):S363-S371.
9. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279:365-370.
10. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage. JAMA 2001; 286:49-56.
11. Klugman KP. Antibiotic selection of multiply resistant pneumococci. Clin Infect Dis 2001; 33:489-491.
12. Reyes H, Guiscafre H, Munoz O, Perez-Cuevas R, Martinez H, Gutierrez G. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997; 50:1297-1304.
13. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002; 49:897-903.
14. Harris CM, Lloyd DC. Consider short courses of antibiotics. BMJ 1994; 308:919.
15. Welage LS, Walawander CA, Timm EG, Grasela TH. Risk factors for acute renal insufficiency in patients with suspected or documented bacterial pneumonia. Ann Pharmacother 1994; 28:515-522.
16. Perez-Gorricho B, Ripoll M; PACE Study Group. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents 2003; 21:222-228.
17. Strausbaugh LJ, Jernigan DB, Liedtke LA. National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network. Clin Infect Dis 2001; 33:1495-1501.
18. Lockhart PB, Brennan MT, Fox PC, Norton HJ, Jernigan DB, Strausbaugh LJ. Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review. Clin Infect Dis 2002; 34:1621-1626.
19. Perencevich EN, Kaye KS, Strausbaugh LJ, Fisman DN, Harris AD. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants. Clin Infect Dis 2004; 38:476-482.
20. Arrow K, Solow R, Portney P, Learner E, Radner R, Schuman H. Report of the National Oceanic and Atmospheric Administration (NOAA) Panel on Contingent Valuation. Washington, DC: NOAA; 1993. Available at: http://www.darp.noaa.gov/ library/pdf/cvblue.pdf. Accessed March 8, 2005.
21. Genne D, Kaiser L, Kinge TN, Lew D. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003; 9:949-954.
22. Butler CC, Kinnersley P, Prout H, Rollnick S, Edwards A, Elwyn G. Antibiotics and shared decision-making in primary care. J Antimicrob Chemother 2001; 48:435-440.
23. Fisman DN, Mittleman MA, Sorock GS, Harris AD. Willingness to pay to avoid sharps-related injuries: a study in injured health care workers. Am J Infect Control 2002; 30:283-287.
24. Neumann PJ, Johannesson M. The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care 1994; 32:686-699.
25. Lee SJ, Neumann PJ, Churchill WH, Cannon ME, Weinstein MC, Johannesson M. Patients' willingness to pay for autologous blood donation. Health Policy 1997; 40:1-12.
26. Lee SJ, Liljas B, Neumann PJ, Weinstein MC, Johannesson M. The impact of risk information on patients' willingness to pay for autologous blood donation. Med Care 1998; 36:1162-1173.
27. Zillich AJ, Blumenschein K, Johannesson M, Freeman P. Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma. Pharmacoeconomics 2002; 20:257-265.
28. Bosch JL, Hammitt JK, Weinstein MC, Hunink MG. Estimating general-population utilities using one binary-gamble question per respondent. Med Decis Making 1998; 18:381-390.
29. Klose T. The contingent valuation method in health care. Health Policy 1999; 47:97-123.
30. Donaldson C, Shackley P, Abdalla M. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 1997; 6:145-159.